Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Neurologic Complications Associated with Hepatitis C Virus Infection
Neurol 53:861-864, Tembl,J.I.,et al, 1999
Clinicopath Conf
Subacute Sclerosing Panencephalitis, Case 15-1998, NEJM 338:1448-1456998., , 1998
Nonsystemic Vasculitic Mononeuropathy Multiplex, Cryoglobulinemia, and Hepatitis C
Muscle & Nerve 19:1596-1602996., David,W.S.,et al, 1996